KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Sep 2025 value amounting to $27.9 million.

  • Rigel Pharmaceuticals' Net Income towards Common Stockholders rose 124.62% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.2 million, marking a year-over-year increase of 2817.96%. This contributed to the annual value of $17.5 million for FY2024, which is 169.61% up from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Net Income towards Common Stockholders stood at $27.9 million, which was down 53.20% from $59.6 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $59.6 million for Q2 2025, and its period low was -$27.4 million during Q1 2022.
  • Over the past 3 years, Rigel Pharmaceuticals' median Net Income towards Common Stockholders value was $737,000 (recorded in 2023), while the average stood at $8.3 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Net Income towards Common Stockholders slumped by 169.48% in 2022, and later surged by 5,887.67% in 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$22.6 million in 2021, then spiked by 106.20% to $1.4 million in 2022, then tumbled by 47.39% to $737,000 in 2023, then surged by 1,843.28% to $14.3 million in 2024, then surged by 124.62% to $27.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at $27.9 million for Q3 2025, versus $59.6 million for Q2 2025 and $11.4 million for Q1 2025.